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Abstract
Background: Non-motor symptoms (NMS) in Parkinson’s disease (PD) differ from those in essential tremor (ET), even before a definitive diagnosis is made. It is
not clear whether patient’s knowledge of the diagnosis and treatment influence their subsequent reporting of NMS.
Methods: 1 year after a clinical and instrumental diagnosis, we compared the motor impairment (Movement Disorders Society (MDS)-Unified Parkinson’s Disease
Rating Scale-III) and non-motor symptoms (NMSQuest) in PD (n531) and ET (n521) patients.
Results: PD patients reported more NMS than did the ET patients (p50.002). When compared to their baseline report, at follow-up, PD patients reported less
nocturia (p50.02), sadness (p50.01), insomnia (p50.02), and restless legs (p50.04) and more nausea (p50.024), unexplained pain (p50.03), weight change
(p50.009), and daytime sleepiness (p50.03). When compared to their baseline report, ET patients reported less loss of interest (p50.03), anxiety (p50.006), and
insomnia (p50.02). Differences in reported weight change (p,0.0001) and anxiety (p50.001) between PD and ET patients were related to pharmacological side
effects or to a reduction in the ET individuals.
Discussion: The reporting of NMS is influenced by subjective factors, and might vary with the patient’s knowledge of the diagnosis or the effectiveness of
treatment.
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Introduction
Parkinson’s disease (PD) is a neurodegenerative disease character-
ized by motor signs (bradykinesia plus tremor, rigidity, or postural
instability, according to the UK PD Brain Bank [UKPDBB] criteria)1
and non-motor symptoms (NMS). NMS in PD include constipation,2
orthostatic hypotension,3 hyposmia,4 rapid eye movement sleep
behavior disorder (RBD),5 neuropsychiatric complaints (anxiety,
depression),6 and cognitive defects.7 Essential tremor (ET) is a
movement disorder characterized by a rhythmic tremor affecting the
hands and forearms.8 ET is associated with relevant NMS, such as
frontal dysfunction, dementia, anxiety, depression, poor sleep quality,
and subjective reduction of hearing.9 We previously demonstrated
that, with respect to their NMS, PD and ET patients are suggestible,10
but despite this, NMS do exist and have been reported by affected
patients who are not aware of their diagnosis. The aim of this study
was to examine self-reports of NMS by PD and ET patients 1 year




The PD and ET patients included in this study were described in our
recently published paper, which notes the inclusion and exclusion criteria.10
The participants were selected from individuals visiting the Operative Unit
for Nuclear Medicine of the General Hospital of Barletta, and who had
received [123I] b-CIT (2b-carbomethoxy-3b-[4-iodophenyl]tropane) single
photon emission computed tomography (SPECT) for diagnostic
purposes over a 6-month period (from March 2012 to September
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2012). All patients provided written informed consent. The patients
were interviewed for clinical history, evaluated with the NMSQuest,11
answered a 30-item self-administered questionnaire evaluating NMS,
and scored for motor symptoms (Unified Parkinson’s Disease Rating
Scale [UPDRS]-III). A diagnosis of PD or ET was made by neurologists
who were not involved in this study, and were made on the basis of the
clinical and instrumental data (imaging and [123I] b-CIT SPECT). A
diagnosis was assigned according to the established diagnostic criteria,1,8
and the diagnosing neurologists were responsible for determining the
treatment. One year after the first evaluation, the selected individuals
(n576) were followed-up to assess the diagnosis of PD based on the
response to dopaminergic therapy and the other UKPDBB supportive
and exclusion criteria. Twenty-three individuals were excluded from the
final study sample because of the appearance of signs or symptoms
suggesting a diagnosis other than PD or ET (namely vascular or
iatrogenic parkinsonism, progressive supranuclear paralysis, Lewy body
dementia, or psychogenic movement disorder). One additional ET
patient was lost at follow-up because of a change of residence. The 24
excluded individuals did not differ from the included study sample with
respect to their age (69.5¡7 years old), gender distribution (16 men),
or duration of symptoms. A diagnosis of PD was confirmed in 31
individuals (9 females, 22 males) 1 year after the first evaluation
according to the following criteria: 1) the presence of a parkinsonian
syndrome, 2) the absence of any exclusion criteria according to the
UKPDBB diagnostic criteria, 3) reduced representation of striatal
dopaminergic nerve terminals according to the Dopamine Transporter
(DAT) scan results, and 4) the response to dopaminergic therapy.
Twenty-two patients (10 females, 12 males) with ET were selected from
the included participants according to published diagnostic criteria.8
The NMS and UPDRS score were re-assessed at the 1-year follow-up
visit.
Statistical analysis
Unpaired t-tests were used to compare the groups with respect to
age, the number of NMS, and UPDRS scores. Fisher’s exact test was
used to compare the frequency of NMS between the PD and ET
groups. The data are expressed as the mean¡SD. InStat software
(GraphPad, La Jolla, CA, USA) was used to perform the statistical
analysis.
Results
Patient demographics, UPDRS, and NMS characteristics at
follow-up
There were no significant differences between the PD (n531) and
ET (n521) patients with regards to the mean age or the male/female
sex distribution. All of the PD patients were taking dopaminergic drugs
at the time of the evaluations. Twenty-five PD patients were taking L-
dopa alone or associated with either a monoamine oxidase B inhibitor
(iMAO-B), a dopamine agonist, or both, and six were taking iMAO-Bs















p Value p Value
Age 69.1¡8.2 70.2¡6.8 0.5 67.6¡9.1 68.6¡7.1 0.7 0.4
Men 22 (71) 22 (71) 1.0 12 (54) 11 (52) 1.0 1.0
UPDRS-III 27.0¡12 16.5¡8 0.0001 4.7¡3 3.4¡2 0.1 ,0.0001
H & Y #2 #2 - - - - -
Tremor 22 (71) 22 (71) 1.0 22 (100) 21 (100) 1.0 0.007
Dopaminergic
therapy
8 (26) 31 (100) ,0.0001 1 (4) 0 (0) 1.0 ,0.0001
Total LEDD (mg/
day)
NA 412¡76 - 0 0 - -
L-dopa 8 (26) 25 (81) ,0.0001 1 (4) 0 (0) 1.0 ,0.0001
NMS 10.4¡4.9 10.2¡6.9 0.1 8.4¡3.3 5¡2.9 0.0009 0.002
Abbreviations: ET, Essential Tremor; H & Y: Hoehn & Yahr score; LEDD, L-dopa-equivalent Daily Dosage; NA, Not Available; NMS, Non-motor Symptoms; PD,
Parkinson’s Disease; UPDRS-III, Unified Parkinson’s Disease Rating Scale.
Numbers in brackets indicate the percentage of patients in that subgroup. Significant p values are shown in bold.
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Table 2. Frequency of Non-motor Symptoms in Parkinson’s Disease and Essential Tremor Patients at Follow-up
Parkinson’s Disease Essential Tremor PD vs ET at
Follow- up
NMS Baseline Follow-up p Value Baseline Follow-up p Value p Value
n531 % n531 % n522 % n521 %
Drooling 9/31 29 5/31 16.1 0.4 1/22 4.5 1/21 4.7 1.0 0.4
Taste/smell 10/31 32.2 14/31 45.2 0.4 1/22 4.5 2/21 9.5 0.6 0.007***
Swallowing 6/31 19.3 7/31 22.6 1.0 4/22 18.1 2/21 9.5 0.6 0.3
Nausea/vomiting 0/31 0 6/31 19.3 0.02 4/22 18.1 2/21 9.5 0.6 0.4
Constipation 6/31 19.3 8/31 25.8 0.8 4/22 18.1 2/21 9.5 0.6 0.2
Bowel incontinence 3/31 10 5/31 16.1 0.7 3/22 13.6 1/21 4.7 0.6 0.7
Incomplete bowel
emptying
6/31 9.6 8/31 25.8 0.7 4/22 18.1 2/21 9.5 0.6 0.2
Urgency 17/31 54.8 18/31 58 1.0 12/22 54.5 8/21 38.0 0.4 0.3
Nocturia 19/31 61.2 9/31 29 0.02 11/22 50 7/21 33.3 0.3 0.8
Pains 11/31 35.4 3/31 9.6 0.03 9/22 41 4/21 19.0 0.2 0.4
Weight 13/31 42 24/31 77.4 0.009 9/22 41 4/21 19.0 0.2 ,0.0001**
Forgetfulness, memory 15/31 48.3 16/31 51.6 1.0 11/22 50 6/21 28.5 0.2 0.2
Loss of interest 19/31 61.2 19/31 61.2 1.0 13/22 59 5/21 23.8 0.03 0.01**
Hallucinations 6/31 19.3 7/31 19.3 1.0 0/22 0 0/21 0 1.0 0.03****
Concentrating 16/31 51.6 15/31 48.4 1.0 5/22 22.7 6/21 28.5 0.7 0.3
Sad, blues 16/31 51.6 6/31 19.3 0.01 11/22 50 5/21 23.8 0.1 1.0
Anxiety 20/31 64.5 22/31 70.1 0.8 15/22 68.1 5/21 23.8 0.006 0.001****
Sex drive 16/31 51.6 15/31 48.4 1.0 11/22 50 8/21 38.0 0.5 0.1
Sex difficulty 9/31 29 9/31 29 1.2 8/22 36.3 7/21 33.3 1.0 0.8
Orthostatic dizziness 21/31 67.7 22/31 70.1 1.0 6/22 27.2 2/21 9.5 0.2 ,0.0001**
Falling 6/31 19.3 9/31 29 0.5 0/22 0 0/21 0 1.0 0.0073***
Daytime sleepiness 3/31 9.6 11/31 35.4 0.03 4/22 18.2 3/21 14.3 1.0 0.1
Insomnia 18/31 58 8/31 25.8 0.02 12/22 50 4/21 19.0 0.02 0.7
Vivid dreams 10/31 32.2 9/31 29 1.0 1/22 4.5 1/21 4.7 1.0 0.036****
Acting out during
dreams
18/31 58 15/31 48.4 0.6 6/22 27.3 3/21 14.3 0.4 0.017****
RLS 9/31 29 2/31 9.6 0.04 8/22 36 4/21 19.0 0.3 0.2
Swelling 7/31 22 7/31 22.5 1.0 5/22 18.1 5/21 23.8 1.0 1.0
Sweating 4/31 12.9 5/31 25.8 0.3 7/22 32 5/21 23.8 0.7 0.5
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plus agonists. None of the ET patients was taking tremor-directed
symptomatic treatments; they had been discouraged from doing so by
their neurologists because of the mildness of their tremors (maximal
amplitude less than 3 cm) relative to the possible eventual occurrence
of drug-related side effects. The UPDRS scores were higher in the PD
than in ET patients (PD 16.5¡8, ET 3.43¡2, p,0.0001). The PD
patients complained of more NMS (10.16¡6.9) than the ET patients
(5¡2.9, p50.002). The results are described in Table 1
Complaints of specific NMS in the PD and ET patients at
follow-up
Changes from baseline (1 year earlier) were observed in the
percentage of PD patients who complained of NMS. The following
NMS decreased: drooling (212.9%), nocturia (232.2%), pain
(225.8%), sadness (232.3%), insomnia (232.2%), and restless legs
syndrome (RLS) (219.4%); the following NMS increased: daytime
sleepiness (+25.8%), taste (+13%), incomplete bowel emptying
(+16.2%), change in weight (+35.4%), and sweating (+12.9%). ET
patients reported the following changes in NMS: urgency (216.5%),
nocturia (216.7%), pain (222%), weight change (222%), forgetful-
ness (221.5%), loss of interest (235.2%), sadness (226.2%), anxiety
(244.3%), reduced sex drive (212%), orthostatic dizziness (217.7%),
and RLS (217%). PD patients exhibited a higher frequency of the
following NMS compared with ET patients: hyposmia, weight change,
loss of interest, hallucinations, anxiety, orthostatic dizziness, falling,
vivid dreams, and acting out during dreams (REM behavior disorder,
RBD). The increased complaints of weight change and orthostatic
dizziness by the PD patients compared with the ET patients was the
most significant results (p,0.0001). None of the ET patients who
reported vomiting were actively consuming central nervous system-
active drugs. See Table 2 and Figure 1 for results.
Discussion
The fundamental finding of our study is that ET patients may
experience spontaneous relief of NMS. We observed a significant and
spontaneous reduction in the number of complaints of several NMS in
these patients, and these patients were not receiving pharmacological
therapy at the time of the follow-up visit. The reduction included NMS
known to frequently affect ET patients, such as loss of interest, anxiety,
and insomnia.10,12,13 As we have previously suggested,10 we hypothesize
that a patient’s perception of symptoms might change after learning
about the diagnosis and the expected symptoms through mass media, the
Internet, and printed information. Although increased reports of
dementia, anxiety, executive deficit, depression, and poor sleep quality
have been associated with ET,9 our findings should not be interpreted as
variant results. The early follow-up (after 1 year from the first assessment)
might only have affected the subjective declaration of NMS, whereas the
appearance of specific NMS due to disease-associated physiopathological
mechanisms would be expected later in the course of ET.
The total number of NMS declared by the PD patients did not
change at the follow-up visit; however, there were changes in some of
the specific symptoms. The number of patients reporting daytime
sleepiness, weight change, and nausea/vomiting increased at 1 year
from the initial evaluation. This finding was in accordance with results
from a previous study14 and is possibly related to the pharmacological
side effects of dopaminergic therapy. Conversely, the same report
described a significant reduction in the number of complaints of
drooling, nocturia, unexplained pain, sadness, insomnia, and RLS in
the identical PD patient sample.14 Although it would be tempting to
suggest that at least some of the reported improvements might be
related to suggestion or adaptive mechanisms, as observed in ET, the
responsiveness of specific NMS to pharmacological therapy has been
extensively described.14,15 Drooling improves due to the dopaminer-
gic-induced reduction of akinesia, nocturia positively responds to
rotigotine,16 and L-Dopa and dopamine agonists have a specific
antidepressant effect through limbic dopamine D3 receptor agonism.17
Sleep-associated disorders, such as insomnia and RLS, typically
improve following dopaminergic therapy.18,19
Due to the decrease in NMS in the ET patients, the total number of
NMS in the PD patients was significantly different from those observed
in the ET patients at follow-up. The PD patients reported the same
number of NMS before and 1-year after diagnosis. The UPDRS part
III score significantly decreased upon treatment initiation, providing a
diagnostic clue suggestive of PD (as encoded by the UKPDBB criteria).
Table 2. Continued
Parkinson’s Disease Essential Tremor PD vs ET at
Follow- up
NMS Baseline Follow-up p Value Baseline Follow-up p Value p Value
n531 % n531 % n522 % n521 %
Diplopia 7/31 22.5 5/31 16.1 0.7 0/22 0 0/21 0 1.0 0.1
Delusions 3/31 9.6 6/31 19.3 0.5 0/22 0 1/21 4.1 0.5 0.2
Abbreviations: ET, Essential Tremor; NMS, Non-motor Symptoms; PD, Parkinson’s Disease RLS, restless legs syndrome.
Fisher’s exact test was used for all statistical comparisons.
Significant values are expressed in bold. *p,0.0001; **p,0.001; ***p,0.01; ****p,0.05.
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This finding was partly in accordance with previous studies that
reported no significant changes in the number of NMS in patients with
PD after 2 years of follow-up14 and a direct correlation between the
total number of NMS and therapy-induced amelioration of the
UPDRS score.20
Our work demonstrates that reports of NMS by patients with
movement disorders are common; however, some NMS in PD appear
to be highly reproducible and responsive to treatment. The major
weakness of our investigation is the small study sample. Although this
reduced the power of the statistical analyses, we do not expect that this
shortcoming biased our findings.
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